{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-26-000312","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2026-08-06T11:35:24+00:00","discovered_at":"2026-08-06T11:40:00.273510+00:00","generated_at":"2026-08-06T11:40:18.106864+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioVie Phase 2 SUNRISE-PD trial of bezisterim shows statistically significant improvements vs placebo","bullets":["Statistically significant improvements on MDS-UPDRS Parts I, II, III and composite EPNIC-15 (p=0.0006).","Bezisterim improved biomarkers of neuroinflammation and systemic inflammation; composite neuroinflammation measure p=0.0018.","283 of 380 proteins shifted toward lower inflammatory burden (binomial p=3.2e-22).","Bezisterim well-tolerated; adverse events 39.3% vs 51.7% placebo, no severe/serious AEs.","Conference call scheduled for Aug 12, 2026 to discuss results."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-26-000312","json":"https://secwatch.observer/filing/0001520138-26-000312.json","markdown":"https://secwatch.observer/filing/0001520138-26-000312.md","text":"https://secwatch.observer/filing/0001520138-26-000312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013826000312/0001520138-26-000312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013826000312/bivi-20260806_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:40:18.106864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}